As exemplified by titles of publication like “Are we on the right TRAIL?” [9], “Targeting TRAIL towards the clinic” [10], “Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy [11], further rational design of TRAIL-based therapy combined with other modality or advances in administration using nano- or cell–carriers is needed as cancer therapeutics [12]. This evidence concerns the gene TNFSF10 and cancer.